Table 1 Prognosis of CTCL patients according to tumour stage at presentation
Stage | Description | Survival |
|---|---|---|
1A | T1, patches and/or plaques involving <10% BSA with no palpable adenopathy | Similar to age-matched controls (Kim et al, 1999; Zackheim et al, 1999) |
1B | T2, patches and/or plaque involving at ⩾10% BSA with no palpable adenopathy | ⩾67% at 10 years (Kim et al, 1999; Zackheim et al, 1999) |
IIA | T1/T2, patches and/or generalised plaque, clinically abnormal lymph nodes | |
IIB | T3, cutaneous tumours | 5 years (Kim and Hoppe, 1999) |
III | T4, generalised erythroderma | |
IVA-B | Pathologically involved lymph nodes or visceral involvement | 2.5 years (Kim and Hoppe, 1999) |
